A new drug, pirfenidone, will be on the market soon

In 2006, the clinical study of pirfenidone was organized by union hospital In 2010, pirfenidone passed the new drug review In September 2011, it obtained the class 1.1 new drug certificate issued by the State Food and drug administration In 2012, "the process upgrading and production line construction project of the new drug pirfenidone for the treatment of pulmonary fibrosis class 1.1" was included in the major equity investment project of the national government The equity financing of Beijing Municipal Science and Technology Commission is 10 million yuan, which is held by Zhongguancun Development Group [English name] pirfenidone [trade name] piresupa [development unit] developed by marnac company of the United States, which licensed the development rights of pirfenidone in Japan, Taiwan and South Korea to yannoyi company of Japan [indications] to treat idiopathic pulmonary fibrosis [dosage form] tablet [Specification] 200mg [usage and dosage] to be taken after meals; 200mg each time, three times a day, to be taken with warm water Also known as "cancer that is not cancer", the lung function of the patients continues to decline, and the average survival period is only 2 to 5 years Once the patient's lung becomes a fibrotic "honeycomb lung", sneezing, coughing and catching a cold can kill the patient The incidence rate of incidence of disease in the past few years is very low In recent years, the incidence rate of the city is increasing, and the incidence of the disease is expanding However, there is no effective treatment "There are 14.7 cases per 100000 people, increasing at an annual rate of 11%." According to Dr Luo Ying, chairman and chief scientist of Contini company, there are 3000 to 5000 people suffering from the disease every year in the country who have no medicine to treat The union hospital alone receives 2300 patients every year 1 Main symptoms (1) dyspnea, exertive dyspnea and progressive aggravation, shallow breathing speed, nasal flap movement and auxiliary muscles may participate in breathing, but most of them do not sit upright (2) There is no cough in the early stage of cough and expectoration, and there may be dry cough or a small amount of mucus sputum later, which is easy to have secondary infection Mucopurulent sputum or purulent sputum, occasionally bloody sputum (3) General symptoms can be emaciation, fatigue, anorexia, joint pain, etc., which are generally rare, acute type can have fever 2 Common signs (1) dyspnea and cyanosis (2) Thoracic dilatation and decreased diaphragmatic activity (3) Velcro rales in the middle and lower lungs are characteristic (4) Clubbing toes (5) The corresponding signs of end-stage respiratory failure and right heart failure In 2006, the clinical study of pirfenidone was organized by union hospital In 2010, pirfenidone passed the new drug review In September 2011, it obtained the class 1.1 new drug certificate issued by the State Food and drug administration In 2012, "the process upgrading and production line construction project of the new drug pirfenidone for the treatment of pulmonary fibrosis class 1.1" was included in the major equity investment project of the national government The equity financing of Beijing Municipal Science and Technology Commission is 10 million yuan, which is held by Zhongguancun Development Group